| Project/Area Number |
15591681
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Shiga University of Medical Science |
|---|
Principal Investigator |
WAKABAYASHI Yoshihiko Shiga University of Medical Science, Medicine, Lecturer, 医学部, 講師 (80191724)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YOSHIKI Tatsuhiro Shiga University of Medical Science, Medicine, Associate professor, 医学部, 助教授 (80230704)
KIM Chul-jang Shiga University of Medical Science, Medicine, Lecturer, 医学部, 講師 (10204968)
JOHNIN Kazuyoshi Shiga University of Medical Science, Medicine, Assistant, 医学部, 助手 (90324590)
|
|---|
| Project Period (FY) |
2003 – 2004
|
| Project Status |
Completed (Fiscal Year 2004)
|
| Budget Amount *help |
¥3,500,000 (Direct Cost: ¥3,500,000)
Fiscal Year 2004: ¥1,300,000 (Direct Cost: ¥1,300,000)
Fiscal Year 2003: ¥2,200,000 (Direct Cost: ¥2,200,000)
|
|---|
| Keywords | Urothelial Cancer / Tumor Marker / Calreticulin / Proteomics |
|---|
| Research Abstract |
We achieved some results in this project as follow.
(1)Establishment of diagnostic accuracy by urinary calreticulin (CRT) in bladder cancer.
We performed the proteome analysis of bladder cancer using narrow pH range two-dimensional gel electrophoresis, and found calreticulin is a good urinary marker for bladder cancer. By immunoblot analysis using anti-CRT polyclonal antibody, we could detect CRT in urine of many patients with bladder urothelial carcinoma. In 251 urine samples, sensitivity and specificity of urinary CRT test were 73 % and 86 %, respectively. The results were published in the journal, Clinical Chemistry, in 2004.
(2)Development of combined marker using urinary CRT, gamma-synuclein (SNCG), and catecol-o-methyltransferase (COMT).
We also found up-expression of SNCG and COMT in proteome analysis of bladder cancer. These two proteins could be detected in urine of the patients with urothelial cancer. Urinary CRT test alone revealed that sensitivity and specificity were 71.4% and 77.4% in 342 urine samples, respectively. Otherwise, combined detection test showed better diagnostic values, 77.4% and 77.8%, respectively. The result was published in Cancer Science in 2004.
(3)ELISA kit for urinary CRT.
We produced recombinant human CRT protein by BL-21 E.coli. as a standard material in ELISA for CRT. We succeeded to establish ELISA kit using two commercially available anti-CRT antibodies. When the cut-off value was defined at 5ng/mL, positive results were obtained in 65% of 109 samples of bladder cancer patients and 5% of 40 healthy samples, respectively. These are unpublished data.
|
